Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing open-label study of recombinant human thrombopoietin injection in children with primary immune thrombocytopenia
CTR20261475Phase 4Active
- Sponsor
- 3SBio
- Start
- Apr 2026
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human thrombopoietin in immune thrombocytopenia (ITP), sponsored by 3SBio. Started Apr 2026; status: active.
02
Drugs
recombinant human thrombopoietin
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20261475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261475.